Deutsche Bank Aktiengesellschaft restated their hold rating on shares of GSK (LON:GSK – Free Report) in a research note published on Thursday morning,Digital Look reports. They currently have a GBX 2,000 price target on the stock.
GSK has been the topic of a number of other research reports. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a report on Tuesday, October 20th. Berenberg Bank boosted their target price on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday, September 15th. Finally, Royal Bank Of Canada started coverage on shares of GSK in a research report on Tuesday, September 8th. They set a “sector perform” rating and a GBX 1,975 target price on the stock. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of GBX 2,064.38.
Check Out Our Latest Analysis on GSK
GSK Price Performance
Shares of GSK stock opened at GBX 1,850 on Thursday. GSK has a 52 week low of GBX 1,690 and a 52 week high of GBX 2,282. The stock has a market capitalization of £74.13 billion, a PE ratio of 15.70, a PEG ratio of 1.24 and a beta of 0.28. The company has a debt-to-equity ratio of 126.38, a quick ratio of 0.73 and a current ratio of 0.86. The stock’s fifty day moving average is GBX 1,845.48 and its 200-day moving average is GBX 1,948.89.
GSK (LON:GSK – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The company reported GBX 54.60 earnings per share (EPS) for the quarter. GSK had a return on equity of 24.64% and a net margin of 12.97%. The business had revenue of GBX 888.70 billion during the quarter. Equities research analysts expect that GSK will post 175.98 EPS for the current fiscal year.
Insider Buying and Selling
In other GSK news, insider Jonathan Symonds bought 1,500 shares of the stock in a transaction on Friday, September 18th. The stock was purchased at an average price of GBX 1,881 per share, with a total value of £28,215. Also, insider Anne Beal bought 637 shares of the stock in a transaction on Friday, September 18th. The shares were acquired at an average cost of GBX 4,985 per share, with a total value of £31,754.45. Over the last ninety days, insiders acquired 2,151 shares of company stock worth $6,021,921. Insiders own 0.20% of the company’s stock.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Further Reading
- Five stocks we like better than GSK
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
